Supplemental Online Content

Pichert MD, Canavan ME, Maduka RC, et al. Immunotherapy after chemotherapy and radiation for clinical stage III lung cancer. *JAMA Netw Open.* 2022;5(8):e2224478. doi:10.1001/jamanetworkopen.2022.24478

eTable 1. Propensity-Matched Baseline Characteristics and Standardized Mean Differences of Patients Receiving Chemotherapy and Radiation Followed By Immunotherapy vs Chemotherapy and Radiation Only

eTable 2. CONSORT Diagram

eFigure. Unmatched Kaplan-Meier Curve with Survival of Stage III NSCLC Patients Who Received Chemotherapy and Radiation Only Compared to Patients Who Received Chemotherapy and Radiation Followed by Immunotherapy

eTable 3. Cox Proportional Hazards Model of Stage III NSCLC Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Chemotherapy and Radiation Only

eTable 4. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Patients Who Received Chemotherapy and Radiation Only for Stage III NSCLC With Radiation Doses as Covariates

eTable 5. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy for Stage III NSCLC With Radiation Dose as a Covariate

eTable 6. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy vs Patients Who Received Chemotherapy and Radiation Only for Stage III NSCLC With Time Between Radiation Completion and Starting Immunotherapy as a Covariate

eTable 7. Cox Proportional Hazards Model of Patients Who Received Chemotherapy and Radiation With Immunotherapy for Stage III NSCLC With Time to Immunotherapy Within the PACIFIC Trial Limits and Outside the PACIFIC Trial Limits as a Covariate

eTable 8. Previously Reported Hazard Ratios for Overall Survival Comparing Durvalumab Plus Chemoradiation to Chemoradiation Alone

eTable 9. *P* Values Before and After Benjamini-Hochberg Multiple Testing Adjustment

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable 1.** Propensity-Matched Baseline Characteristics and Standardized Mean Differences of Patients Receiving Chemotherapy and Radiation Followed By Immunotherapy vs Chemotherapy and Radiation Only.

|                     | Chemoradiation Only (%) | Chemoradiation Followed by Immunotherapy (%) | Standardized Mean Difference | P value |
|---------------------|--------------------------|---------------------------------------------|-----------------------------|---------|
| Total Patients      | 2,594 (66.7)             | 1,297 (33.3)                                |                             |         |
| Age (yrs)           |                          |                                             |                             | .76     |
| 20-49               | 98 (64.1)                | 55 (36)                                     | Ref                         |         |
| 50-64               | 1,016 (66.2)             | 519 (33.8)                                  | -.01734                     |         |
| 65-74               | 1,058 (67.5)             | 509 (32.5)                                  | 0.03148                     |         |
| ≥75                 | 422 (66.4)               | 214 (33.7)                                  | -.00625                     |         |
| Sex                 |                          |                                             |                             | .73     |
| Male                | 1,381 (66.4)             | 698 (33.6)                                  | Ref                         |         |
| Female              | 1,213 (66.9)             | 599 (33.1)                                  | .01159                      |         |
| Race                |                          |                                             |                             | .69     |
| White               | 2,193 (66.7)             | 1,094 (33.3)                                | Ref                         |         |
| Black               | 309 (67)                 | 152 (33)                                    | 0.00597                     |         |
| Asian               | 72 (66.7)                | 36 (33.3)                                   | 0.0                         |         |
| Other/Unknown       | 20 (57.1)                | 15 (42.9)                                   | -.03947                     |         |
| Ethnicity           |                          |                                             |                             | .59     |
| Non-Hispanic        | 2,505 (66.8)             | 1,245 (33.2)                                | Ref                         |         |
| Hispanic            | 46 (61.3)                | 29 (38.7)                                   | -.03301                     |         |
| Unknown             | 43 (65.2)                | 23 (34.9)                                   | -.00891                     |         |
| Insurance           |                          |                                             |                             | .70     |
| Private             | 844 (67.1)               | 413 (32.9)                                  | Ref                         |         |
| Medicare            | 1,394 (66.9)             | 689 (33.1)                                  | 0.01237                     |         |
| Medicaid            | 212 (63.1)               | 124 (36.9)                                  | -.04884                     |         |
| Uninsured           | 50 (63.3)                | 29 (36.7)                                   | -.0216                      |         |
| Other Government    | 58 (68.2)                | 27 (31.8)                                   | 0.01061                     |         |
| Unknown             | 36 (70.6)                | 15 (29.4)                                   | 0.02064                     |         |
| Median Income       |                          |                                             |                             | .86     |
| <$38,000            | 401 (66.1)               | 206 (33.9)                                  | Ref                         |         |
| $38,000-$47,999     | 596 (67.7)               | 285 (32.4)                                  | 0.02401                     |         |
| ≥$48,000            | 1,174 (66.2)             | 600 (33.8)                                  | -.02012                     |         |
| Unknown             | 423 (67.3)               | 206 (32.8)                                  | 0.01154                     |         |
| Year of Diagnosis   |                          |                                             |                             | .89     |
| 2015                | 125 (65.5)               | 66 (34.6)                                   | Ref                         |         |
| 2016                | 163 (67.6)               | 78 (32.4)                                   | 0.01123                     |         |
| 2017                | 2,306 (66.7)             | 1,153 (33.3)                                | 0.0                         |         |
| Charlson-Deyo Score |                          |                                             |                             | 1.00    |
| 0                   | 1,501 (66.7)             | 748 (33.3)                                  | Ref                         |         |
| 1                   | 678 (66.6)               | 340 (33.4)                                  | -.00175                     |         |
| 2                   | 259 (66.4)               | 131 (33.6)                                  | -.00385                     |         |
| 3                   | 156 (66.7)               | 78 (33.3)                                   | 0.0                         |         |
**eTable 1 Continued.**

| Histology         | Ref          | T Category | Ref          | N Category | Facility Type | Ref          | Region | Ref          |
|-------------------|--------------|------------|--------------|------------|---------------|--------------|--------|--------------|
| Adenocarcinoma    | 1,207 (67.1) | 591 (32.9) | Ref          |            |               |              |        |              |
| Squamous Cell     | 1,144 (66.3) | 581 (33.7) | -0.01396     |            |               |              |        |              |
| Large Cell        | 25 (71.4)    | 10 (28.6)  | 0.02079      |            |               |              |        |              |
| Other             | 218 (65.5)   | 115 (34.5) | -0.01647     |            |               |              |        |              |
| **Histology**     | **Ref**      | **T Category** | **N Category** | **Facility Type** | **Region** | **Ref** | **West** | **-0.02057** |
| Adenocarcinoma    | 1,207 (67.1) | 591 (32.9) | Ref          |            |               |              |        |              |
| Squamous Cell     | 1,144 (66.3) | 581 (33.7) | -0.01396     |            |               |              |        |              |
| Large Cell        | 25 (71.4)    | 10 (28.6)  | 0.02079      |            |               |              |        |              |
| Other             | 218 (65.5)   | 115 (34.5) | -0.01647     |            |               |              |        |              |
eTable 2. Consort Diagram.

Patients Who Received Multiagent Chemotherapy and at least 45Gy Radiation N=26,029

498 Patients

Immunotherapy Administered After Chemoradiation N= 25,531

1,720 Patients

Landmark Survival ≥6 Weeks After Completion of Radiation N= 23,811
eFigure 1. Unmatched Kaplan-Meier Curve with Survival of Stage III NSCLC Patients who Received Chemotherapy and Radiation Only Compared to Patients who Received Chemotherapy and Radiation Followed by Immunotherapy.

Product-Limit Survival Estimates
With Number of Subjects at Risk and 95% Confidence Limits

Red = Chemotherapy and Radiation then Immunotherapy
Blue = Chemotherapy and Radiation Only

+ Censored
Logrank p < .0001

0 10 20 30
Months From Diagnosis

22514 21346 17348 13981 10977 7099 5414
1297 1255 1068 835 513 185 56

Chemotherapy and Radiation only median survival is 30.72 (29.90, 31.41)
Immunotherapy median survival is 36.21 (33.22, 48.82)
**Table 3.** Cox Proportional Hazards Model of Stage III NSCLC Patients who Received Chemotherapy and Radiation with Immunotherapy vs Chemotherapy and Radiation Only.

|                           | Hazard Ratio (95% CI) | P value |
|---------------------------|-----------------------|---------|
| **Immunotherapy**         |                       |         |
| Chemoradiation Only       | Reference             |         |
| Immunotherapy After       | 0.74 (0.67 - 0.82)    | <.001   |
| Chemoradiation            |                       |         |
| **Age (yrs)**             |                       |         |
| 20-49                     | Reference             |         |
| 50-64                     | 1.13 (1.01 - 1.27)    | .03     |
| 65-74                     | 1.22 (1.09 - 1.38)    | .001    |
| ≥75                       | 1.51 (1.33 - 1.71)    | <.001   |
| **Sex**                   |                       |         |
| Male                      | Reference             |         |
| Female                    | 0.82 (0.79 - 0.85)    | <.001   |
| **Race**                  |                       |         |
| White                     | Reference             |         |
| Black                     | 0.87 (0.82 - 0.92)    | <.001   |
| Asian                     | 0.70 (0.61 - 0.8)     | <.001   |
| **Ethnicity**             |                       |         |
| Non-Hispanic              | Reference             |         |
| Hispanic                  | 0.79 (0.70 - 0.89)    | <.001   |
| **Insurance**             |                       |         |
| Private                   | Reference             |         |
| Medicare                  | 1.15 (1.09 - 1.21)    | <.001   |
| Medicaid                  | 1.16 (1.08 - 1.24)    | <.001   |
| Uninsured                 | 1.12 (0.97 - 1.28)    | .12     |
| Other Government          | 1.03 (0.90 - 1.17)    | .70     |
| **Median Income**         |                       |         |
| <$38,000                  | Reference             |         |
| $38,000-$47,999           | 0.98 (0.92 - 1.04)    | .45     |
| ≥$48,000                  | 0.92 (0.87 - 0.97)    | .002    |
| **Year of Diagnosis**     |                       |         |
| 2015                      | Reference             |         |
| 2016                      | 0.93 (0.89 - 0.97)    | <.001   |
| 2017                      | 0.92 (0.88 - 0.97)    | .001    |
| **Charlson-Deyo Score**   |                       |         |
| 0                         | Reference             |         |
| 1                         | 1.09 (1.05 - 1.14)    | <.001   |
| 2                         | 1.17 (1.1 - 1.24)     | <.001   |
| 3                         | 1.29 (1.19 - 1.4)     | <.001   |
| **Histology**             |                       |         |
| Adenocarcinoma            | Reference             |         |
| Squamous Cell             | 1.21 (1.16 - 1.26)    | <.001   |
| Large Cell                | 1.41 (1.22 - 1.64)    | <.001   |
| Other                     | 1.23 (1.16 - 1.31)    | <.001   |
### eTable 3 Continued.

| T Category | Hazard Ratio (95% CI) | P Value |
|------------|----------------------|---------|
| 0          | 0.85 (0.62 - 1.17)   | .31     |
| 1          |                      |         |
| 2          | 1.22 (1.16 - 1.29)   | <.001   |
| 3          | 1.39 (1.31 - 1.47)   | <.001   |
| 4          | 1.45 (1.37 - 1.54)   | <.001   |

| N Category | Hazard Ratio (95% CI) | P Value |
|------------|----------------------|---------|
| 0          |                      |         |
| 1          | 1.10 (1.00 - 1.22)   | .05     |
| 2          | 1.36 (1.26 - 1.47)   | <.001   |
| 3          | 1.66 (1.53 - 1.81)   | <.001   |

| Facility Type | Hazard Ratio (95% CI) | P Value |
|---------------|----------------------|---------|
| Non-Academic  |                      |         |
| Academic      | 0.88 (0.84 - 0.92)   | <.001   |

| Region        | Hazard Ratio (95% CI) | P Value |
|---------------|----------------------|---------|
| Northeast     |                      |         |
| Midwest       | 1.00 (0.94 - 1.06)   | 1.00    |
| South         | 0.96 (0.91 - 1.02)   | .21     |
| West          | 0.94 (0.87 - 1.02)   | .14     |

*Age was run as a categorical variable, as there are differences in treatment safety and effectiveness outcomes associated with specific subsets of older patients. Separate model using age a continuous variable was performed and results did not differ (data available upon request).*

*Total N = 23,811 with 12,481 events*
**eTable 4.** Cox Proportional Hazards Model of Patients who Received Chemotherapy and Radiation with Immunotherapy vs Patients who Received Chemotherapy and Radiation Only for Stage III NSCLC With Radiation Doses as Covariates.

| Radiation Dose                  | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| Less Than PACIFIC (45-53 Gy)    | 0.97 (0.93 – 1.03)    | .34     |
| PACIFIC Low (54-50 Gy)          | 1.01 (0.94 – 1.08)    | .84     |
| PACIFIC Mid (60 Gy)             | Reference             |         |
| PACIFIC High (61-66 Gy)         | 0.99 (0.95 – 1.04)    | .79     |
| Greater Than PACIFIC (≥67 Gy)   | 0.97 (0.89 – 1.06)    | .53     |

| Immunotherapy                   | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| Chemoradiation Only             | Reference             |         |
| Immunotherapy After Chemoradiation | 0.74 (0.67 - 0.82) | <.001   |

| Age (yrs)                       | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| 20-49                           | Reference             |         |
| 50-64                           | 1.13 (1.01 - 1.27)    | .03     |
| 65-74                           | 1.22 (1.08 - 1.38)    | .001    |
| ≥75                             | 1.51 (1.33 - 1.70)    | <.001   |

| Sex                             | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| Male                            | Reference             |         |
| Female                          | 0.82 (0.79 - 0.85)    | <.001   |

| Race                            | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| White                           | Reference             |         |
| Black                           | 0.87 (0.82 - 0.92)    | <.001   |
| Asian                           | 0.70 (0.61 - 0.80)    | <.001   |

| Ethnicity                       | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| Non-Hispanic                    | Reference             |         |
| Hispanic                        | 0.79 (0.70 - 0.89)    | <.001   |

| Insurance                       | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| Private                         | Reference             |         |
| Medicare                        | 1.15 (1.09 - 1.21)    | <.001   |
| Medicaid                        | 1.16 (1.08 - 1.24)    | <.001   |
| Uninsured                       | 1.11 (0.97 - 1.28)    | .12     |
| Other Government                | 1.02 (0.90 - 1.17)    | .71     |

| Median Income                   | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| <$38,000                        | Reference             |         |
| $38,000-$47,999                 | 0.98 (0.92 - 1.04)    | .44     |
| ≥$48,000                        | 0.92 (0.87 - 0.97)    | .002    |

| Year of Diagnosis               | Hazard Ratio (95% CI) | P value |
|---------------------------------|-----------------------|---------|
| 2015                            | Reference             |         |
| 2016                            | 0.93 (0.89 - 0.97)    | <.001   |
| 2017                            | 0.92 (0.88 - 0.97)    | <.001   |

© 2022 Pichert MD et al. *JAMA Network Open.*
eTable 4 Continued.

| Charlson-Deyo Score | Reference                  |     |
|---------------------|----------------------------|-----|
| 0                   | Reference                  |     |
| 1                   | 1.09 (1.05 - 1.14)         | <.001|
| 2                   | 1.17 (1.1 - 1.24)          | <.001|
| 3                   | 1.29 (1.19 - 1.4)          | <.001|

| Histology           | Reference                  |     |
|---------------------|----------------------------|-----|
| Adenocarcinoma      | Reference                  |     |
| Squamous Cell       | 1.21 (1.16 - 1.26)         | <.001|
| Large Cell          | 1.41 (1.22 - 1.64)         | <.001|
| Other               | 1.23 (1.15 - 1.31)         | <.001|

| T Category          | Reference                  |     |
|---------------------|----------------------------|-----|
| 0                   | Reference                  |     |
| 1                   | 0.85 (0.62 - 1.17)         | .31 |
| 2                   | 1.22 (1.16 - 1.29)         | <.001|
| 3                   | 1.39 (1.31 - 1.47)         | <.001|
| 4                   | 1.45 (1.37 - 1.54)         | <.001|

| N Category          | Reference                  |     |
|---------------------|----------------------------|-----|
| 0                   | Reference                  |     |
| 1                   | 1.10 (1.00 - 1.22)         | .05 |
| 2                   | 1.36 (1.26 - 1.47)         | <.001|
| 3                   | 1.66 (1.52 - 1.81)         | <.001|

| Facility Type       | Reference                  |     |
|---------------------|----------------------------|-----|
| Non-Academic        | Reference                  |     |
| Academic            | 0.88 (0.84 - 0.92)         | <.001|

| Region              | Reference                  |     |
|---------------------|----------------------------|-----|
| Northeast           | Reference                  |     |
| Midwest             | 1.00 (0.94 - 1.06)         | .99 |
| South               | 0.96 (0.91 - 1.02)         | .21 |
| West                | 0.94 (0.87 - 1.02)         | .14 |

*Total N = 23,811 with 12,481 events
**eTable 5.** Cox Proportional Hazards Model of Patients who Received Chemotherapy and Radiation with Immunotherapy for Stage III NSCLC with Radiation Dose as a Covariate.

| Radiation Dose (95% CI)   | P Value |
|---------------------------|---------|
| 40-53 Gy 1.16 (0.87 - 1.55) | .32     |
| 54-59 Gy 1.00 (0.69 - 1.46) | .99     |
| 60 Gy Reference           |         |
| 61-66 Gy 0.94 (0.74 - 1.20) | .64     |
| ≥67GY 0.92 (0.57 - 1.48)  | .73     |
| Age (yrs)                 |         |
| 20-49 Reference           |         |
| 50-64 1.13 (0.66 - 1.94)  | .66     |
| 65-74 0.94 (0.53 - 1.69)  | .85     |
| ≥75 0.98 (0.53 - 1.82)    | .96     |
| Sex                       |         |
| Male Reference            |         |
| Female 0.86 (0.71 - 1.05) | .13     |
| Race                      |         |
| White Reference           |         |
| Black 0.75 (0.54 - 1.05)  | .09     |
| Asian 0.28 (0.10 - 0.76)  | .01     |
| Ethnicity                 |         |
| Non-Hispanic Reference    |         |
| Hispanic 0.74 (0.35 - 1.57) | .44   |
| Insurance                 |         |
| Private Reference         |         |
| Medicare 1.11 (0.84 - 1.47) | .45   |
| Medicaid 0.95 (0.65 - 1.37) | .77   |
| Uninsured 1.09 (0.55 - 2.16) | .50   |
| Other Government 0.78 (0.38 - 1.57) | .48   |
| Median Income             |         |
| <$38,000 Reference        |         |
| $38,000-$47,999 0.84 (0.60 - 1.17) | .29   |
| ≥$48,000 0.72 (0.53 - 0.97) | .03   |
| Year of Diagnosis | Reference | 2015 | 2016 | 2017 |
|-------------------|-----------|------|------|------|
|                   |           | 1.00 | 0.63 | 1.58 |
|                   |           |      | .99  |      |
|                   |           | 0.73 | 0.51 | 1.06 |
|                   |           |      | .09  |      |
| Charlson-Deyo Score |         |      |      |      |
| 0                 | Reference |      |      |      |
| 1                 | 1.14 (0.91 - 1.43) | .24 |
| 2                 | 1.47 (1.07 - 2.01)  | .02 |
| 3                 | 1.50 (1.03 - 2.18)  | .04 |
| Histology         |           |      |      |      |
| Adenocarcinoma    | Reference |      |      |      |
| Squamous Cell     | 1.54 (1.25 - 1.89)  | <.001|
| Large Cell        | 2.13 (0.90 - 5.04)  | .09 |
| Other             | 0.77 (0.51 - 1.17)  | .23 |
| T Category        |           |      |      |      |
| 1                 | Reference |      |      |      |
| 2                 | 1.34 (0.98 - 1.82)  | .06 |
| 3                 | 1.46 (1.05 - 2.02)  | .02 |
| 4                 | 1.51 (1.08 - 2.11)  | .02 |
| N Category        |           |      |      |      |
| 0                 | Reference |      |      |      |
| 1                 | 0.87 (0.49 - 1.53)  | .62 |
| 2                 | 1.21 (0.78 - 1.86)  | .39 |
| 3                 | 1.66 (1.04 - 2.64)  | .03 |
| Facility Type     |           |      |      |      |
| Non-Academic      | Reference |      |      |      |
| Academic          | 0.80 (0.64 - 0.99)  | .04 |
| Region            |           |      |      |      |
| Northeast         | Reference |      |      |      |
| Midwest           | 0.97 (0.73 - 1.29)  | .83 |
| South             | 0.96 (0.72 - 1.27)  | .77 |
| West              | 0.85 (0.58 - 1.24)  | .39 |

*Total N = 1,297 with 439 events*
**Table 6.** Cox Proportional Hazards Model of Patients who Received Chemotherapy and Radiation with Immunotherapy vs Patients who Received Chemotherapy and Radiation Only for Stage III NSCLC with Time Between Radiation Completion and Starting Immunotherapy as a Covariate.

| Time to Immunotherapy | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| No Immunotherapy      | Reference             |         |
| ≤6 Weeks              | 0.78 (0.68 - 0.90)    | <.001   |
| 7-9 Weeks             | 0.71 (0.59 - 0.84)    | <.001   |
| 10-12 Weeks           | 0.61 (0.47 - 0.79)    | <.001   |
| >12 Weeks             | 0.75 (0.61 - 0.92)    | .01     |
| Age (yrs)             |                       |         |
| 20-49                 | Reference             |         |
| 50-64                 | 1.13 (1.01 - 1.27)    | .03     |
| 65-74                 | 1.22 (1.09 - 1.38)    | .01     |
| ≥75                   | 1.51 (1.33 - 1.71)    | <.001   |
| Sex                   |                       |         |
| Male                  | Reference             |         |
| Female                | 0.82 (0.79 - 0.85)    | <.001   |
| Race                  |                       |         |
| White                 | Reference             |         |
| Black                 | 0.87 (0.82 - 0.92)    | <.001   |
| Asian                 | 0.70 (0.61 - 0.80)    | <.001   |
| Ethnicity             |                       |         |
| Non-Hispanic          | Reference             |         |
| Hispanic              | 0.79 (0.70 - 0.89)    | <.001   |
| Insurance             |                       |         |
| Private               | Reference             |         |
| Medicare              | 1.15 (1.09 - 1.21)    | <.001   |
| Medicaid              | 1.15 (1.07 - 1.24)    | <.001   |
| Uninsured             | 1.12 (0.98 - 1.28)    | .11     |
| Other Government      | 1.02 (0.90 - 1.17)    | .71     |
| Median Income         |                       |         |
| <$38,000              | Reference             |         |
| $38,000-$47,999       | 0.98 (0.92 - 1.04)    | .45     |
| ≥$48,000              | 0.92 (0.87 - 0.97)    | .002    |
| Year of Diagnosis     |                       |         |
| 2015                  | Reference             |         |
| 2016                  | 0.93 (0.89 - 0.97)    | .001    |
| 2017                  | 0.92 (0.88 - 0.97)    | .001    |
| Charlson-Deyo Score   |                       |         |
| 0                     | Reference             |         |
| 1                     | 1.09 (1.05 - 1.14)    | <.001   |
| 2                     | 1.17 (1.10 - 1.24)    | <.001   |
| 3                     | 1.29 (1.19 - 1.40)    | <.001   |
| Histology             |                       |         |
| Adenocarcinoma        | Reference             |         |
| Squamous Cell         | 1.21 (1.16 - 1.26)    | <.001   |
| Large Cell            | 1.41 (1.22 - 1.63)    | <.001   |
| Other                 | 1.23 (1.16 - 1.31)    | <.001   |
**eTable 6 Continued.**

| T Category | OR (95% CI) | P Value |
|------------|------------|---------|
| 0          | 0.85 (0.62 - 1.17) | .32     |
| 1          | Reference   |         |
| 2          | 1.22 (1.16 - 1.29) | <.001  |
| 3          | 1.39 (1.32 - 1.47) | <.001  |
| 4          | 1.45 (1.37 - 1.54) | <.001  |

| N Category | OR (95% CI) | P Value |
|------------|------------|---------|
| 0          | Reference  |         |
| 1          | 1.10 (1 - 1.22) | .06     |
| 2          | 1.36 (1.26 - 1.47) | <.001  |
| 3          | 1.66 (1.53 - 1.81) | <.001  |

| Facility Type | OR (95% CI) | P Value |
|---------------|------------|---------|
| Non-Academic  | Reference  |         |
| Academic      | 0.88 (0.84 - 0.92) | <.001  |

| Region | OR (95% CI) | P Value |
|--------|------------|---------|
| Northeast | Reference |         |
| Midwest  | 1.00 (0.94 - 1.06) | .99     |
| South    | 0.96 (0.91 - 1.02) | .20     |
| West     | 0.94 (0.87 - 1.02) | .15     |

*Total N = 23,811 with 12,481 events*
### eTable 7. Cox Proportional Hazards Model of Patients who Received Chemotherapy and Radiation with Immunotherapy for Stage III NSCLC with Time to Immunotherapy within the PACIFIC Trial Limits and Outside the PACIFIC Trial Limits as a Covariate.

| Time to Immunotherapy | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| ≤2 weeks              | Reference             |         |
| 3-6 Weeks             | 1.40 (0.79 - 2.49)    | .25     |
| >6 Weeks              | 1.27 (0.72 - 2.24)    | .41     |

| Age (yrs)             | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| 20-49                 | Reference             |         |
| 50-64                 | 1.17 (0.68 - 2.01)    | .57     |
| 65-74                 | 0.98 (0.55 - 1.77)    | .96     |
| ≥75                   | 1.01 (0.54 - 1.87)    | .98     |

| Sex                   | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| Male                  | Reference             |         |
| Female                | 0.85 (0.70 - 1.04)    | .12     |

| Race                  | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| White                 | Reference             |         |
| Black                 | 0.75 (0.54 - 1.04)    | .08     |
| Asian                 | 0.29 (0.10 - 0.79)    | .02     |

| Ethnicity             | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| Non-Hispanic          | Reference             |         |
| Hispanic              | 0.78 (0.37 - 1.63)    | .50     |

| Insurance             | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| Private               | Reference             |         |
| Medicare              | 1.11 (0.83 - 1.47)    | .48     |
| Medicaid              | 0.94 (0.65 - 1.37)    | .76     |
| Uninsured             | 1.17 (0.60 - 2.29)    | .64     |
| Other Government      | 0.75 (0.37 - 1.52)    | .42     |

| Median Income         | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| <$38,000              | Reference             |         |
| $38,000-$47,999       | 0.84 (0.60 - 1.17)    | .29     |
| ≥$48,000              | 0.71 (0.53 - 0.96)    | .03     |

| Year of Diagnosis     | Hazard Ratio (95% CI) | P value |
|-----------------------|-----------------------|---------|
| 2015                  | Reference             |         |
| 2016                  | 0.98 (0.60 - 1.57)    | .92     |
| 2017                  | 0.73 (0.50 - 1.06)    | .10     |
### eTable 7 Continued.

| Charlson-Deyo Score | Reference | 0 | 1.13 (0.90 - 1.41) | .30 |
|---------------------|-----------|---|-------------------|----|
| 2                   | Reference | 0 | 1.49 (1.09 - 2.04) | .01 |
| 3                   | Reference | 0 | 1.52 (1.04 - 2.22) | .03 |
| **Histology**       |           |   |                   |    |
| Adenocarcinoma      | Reference | 0 | 1.51 (1.23 - 1.86) | <.001 |
| Squamous Cell       | Reference | 0 | 2.00 (0.78 - 5.13) | .15 |
| Large Cell          | Reference | 0 | 0.73 (0.48 - 1.12) | .15 |
| **T Category**      |           |   |                   |    |
| 1                   | Reference | 0 | 1.34 (0.98 - 1.83) | .07 |
| 2                   | Reference | 0 | 1.50 (1.08 - 2.09) | .02 |
| 3                   | Reference | 0 | 1.58 (1.12 - 2.22) | .01 |
| **N Category**      |           |   |                   |    |
| 0                   | Reference | 0 | 0.88 (0.49 - 1.56) | .66 |
| 1                   | Reference | 0 | 1.23 (0.80 - 1.91) | .34 |
| 2                   | Reference | 0 | 1.71 (1.07 - 2.73) | .02 |
| **Facility Type**   |           |   |                   |    |
| Non-Academic        | Reference | 0 | 0.79 (0.63 - 0.98) | .03 |
| Academic            | Reference | 0 |                   |    |
| **Region**          |           |   |                   |    |
| Northeast           | Reference | 0 |                   |    |
| Midwest             | Reference | 0 | 0.97 (0.73 - 1.29) | .84 |
| South               | Reference | 0 | 0.94 (0.71 - 1.25) | .67 |
| West                | Reference | 0 | 0.87 (0.59 - 1.27) | .46 |

*Total N = 1,297 with 439 events*
eTable 8. Previously Reported Hazard Ratios for Overall Survival Comparing Durvalumab Plus Chemoradiation to Chemoradiation Alone.

| Study               | Hazard Ratio       | P Value |
|---------------------|--------------------|---------|
| Desilets et al.¹     | 0.56 (0.37 – 0.85) | .001    |
| Sankar et al.²       | 0.57 (0.50 – 0.66) | <.001   |
| Fukui et al.³        | 0.68 (0.45 – 0.997)| .003    |

References
1. Desilets A, Blanc-Durand F, Lau S, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. *Eur J Cancer*. 2021;142:83-91.
2. Sankar K, Bryant AK, Strohbehn GW, et al. Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. *Cancers*. 2022;14(3).
3. Fukui T, Hosotani S, Soda I, et al. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. *Thorac Cancer*. 2020;11(4):1005-1014.
### eTable 9. P-Values Before and After Benjamini-Hochberg Multiple Testing Adjustment

|                  | Hazard Ratio | Unadjusted p-value | P-value with Benjamini-Hochberg Correction Applied |
|------------------|--------------|--------------------|--------------------------------------------------|
| Male             | 0.71 (0.63-0.81) | 0.0001             | 0.0003                                           |
| White            | 0.75 (0.68-0.84) | 0.0001             | 0.0003                                           |
| Non-Hispanic     | 0.74 (0.67-0.82) | 0.0001             | 0.0003                                           |
| Medicare         | 0.69 (0.6-0.79)  | 0.0001             | 0.0003                                           |
| Income ≥$48,000  | 0.68 (0.6-0.78)  | 0.0001             | 0.0003                                           |
| CDS 0            | 0.72 (0.63-0.82) | 0.0001             | 0.0003                                           |
| Academic         | 0.71 (0.61-0.84) | 0.0001             | 0.0003                                           |
| Non-Academic     | 0.76 (0.67-0.85) | 0.0001             | 0.0003                                           |
| Age 65-74        | 0.68 (0.58-0.79) | 0.0001             | 0.0003                                           |
| Age ≥75 yr       | 0.61 (0.48-0.76) | 0.0001             | 0.0003                                           |
| Clinical N2      | 0.72 (0.63-0.82) | 0.0001             | 0.0003                                           |
| Stage IIIA       | 0.7 (0.61-0.81)  | 0.0001             | 0.0003                                           |
| Non-Squamous     | 0.67 (0.58-0.77) | 0.0001             | 0.0003                                           |
| Clinical T3      | 0.69 (0.56-0.85) | 0.0004             | 0.0011                                           |
| Clinical T4      | 0.73 (0.61-0.87) | 0.0006             | 0.0016                                           |
| CDS 1            | 0.74 (0.62-0.88) | 0.0007             | 0.0018                                           |
| Northeast        | 0.72 (0.58-0.88) | 0.0014             | 0.0033                                           |
| West             | 0.62 (0.46-0.84) | 0.0017             | 0.0038                                           |
| Female           | 0.8 (0.69-0.92)  | 0.0019             | 0.004                                            |
| Stage IIIB       | 0.79 (0.68-0.92) | 0.002              | 0.004                                            |
| Midwest          | 0.77 (0.64-0.91) | 0.0025             | 0.0048                                           |
| South            | 0.78 (0.67-0.92) | 0.0035             | 0.0064                                           |
| Squamous         | 0.82 (0.71-0.94) | 0.0038             | 0.0066                                           |
| Clinical T2      | 0.79 (0.66-0.94) | 0.0066             | 0.011                                            |
| Income $38,000-$47,999 | 0.77 (0.63-0.94) | 0.01               | 0.016                                            |
| Medicaid         | 0.69 (0.5-0.94)  | 0.0197             | 0.0303                                           |
| Clinical T1      | 0.75 (0.59-0.97) | 0.0252             | 0.0373                                           |
| Clinical N3      | 0.8 (0.66-0.98)  | 0.0269             | 0.0384                                           |
| Asian            | 0.3 (0.1-0.92)   | 0.0353             | 0.0487                                           |
| Clinical N1      | 0.67 (0.44-1.01) | 0.0543             | 0.0724                                           |
| Black            | 0.76 (0.57-1.01) | 0.0582             | 0.0751                                           |
| Age 50-64        | 0.88 (0.76-1.02) | 0.0943             | 0.1179                                           |
| CDS 3            | 1.36 (0.94-1.97) | 0.0995             | 0.1206                                           |
| Private Insurance| 0.88 (0.75-1.04) | 0.1364             | 0.1605                                           |
| Clinical N0      | 0.77 (0.52-1.14) | 0.1875             | 0.2143                                           |
| Income <$38,000  | 0.9 (0.7-1.16)   | 0.4074             | 0.4527                                           |
| Age <50 yr       | 0.85 (0.5-1.44)  | 0.5414             | 0.5853                                           |
| CDS 2            | 0.91 (0.67-1.24) | 0.5571             | 0.5864                                           |
| Hispanic         | 0.87 (0.43-1.79) | 0.7099             | 0.7281                                           |
| Uninsured        | 0.91 (0.45-1.82) | 0.7836             | 0.7836                                           |